Your browser doesn't support javascript.
Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants.
Logue, James; Johnson, Robert M; Patel, Nita; Zhou, Bin; Maciejewski, Sonia; Foreman, Bryant; Zhou, Haixia; Portnoff, Alyse D; Tian, Jing-Hui; Rehman, Asma; McGrath, Marisa E; Haupt, Robert E; Weston, Stuart M; Baracco, Lauren; Hammond, Holly; Guebre-Xabier, Mimi; Dillen, Carly; Madhangi, M; Greene, Ann M; Massare, Michael J; Glenn, Greg M; Smith, Gale; Frieman, Matthew B.
  • Logue J; The Department of Microbiology and Immunology, The University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
  • Johnson RM; Center for Pathogen Research, The University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
  • Patel N; The Department of Microbiology and Immunology, The University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
  • Zhou B; Center for Pathogen Research, The University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
  • Maciejewski S; Novavax, Inc, 21 Firstfield Road, Gaithersburg, MD, 20878, USA.
  • Foreman B; Novavax, Inc, 21 Firstfield Road, Gaithersburg, MD, 20878, USA.
  • Zhou H; Novavax, Inc, 21 Firstfield Road, Gaithersburg, MD, 20878, USA.
  • Portnoff AD; Novavax, Inc, 21 Firstfield Road, Gaithersburg, MD, 20878, USA.
  • Tian JH; Novavax, Inc, 21 Firstfield Road, Gaithersburg, MD, 20878, USA.
  • Rehman A; Novavax, Inc, 21 Firstfield Road, Gaithersburg, MD, 20878, USA.
  • McGrath ME; Novavax, Inc, 21 Firstfield Road, Gaithersburg, MD, 20878, USA.
  • Haupt RE; Novavax, Inc, 21 Firstfield Road, Gaithersburg, MD, 20878, USA.
  • Weston SM; The Department of Microbiology and Immunology, The University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
  • Baracco L; Center for Pathogen Research, The University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
  • Hammond H; The Department of Microbiology and Immunology, The University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
  • Guebre-Xabier M; Center for Pathogen Research, The University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
  • Dillen C; The Department of Microbiology and Immunology, The University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
  • Madhangi M; Center for Pathogen Research, The University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
  • Greene AM; The Department of Microbiology and Immunology, The University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
  • Massare MJ; Center for Pathogen Research, The University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
  • Glenn GM; The Department of Microbiology and Immunology, The University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
  • Smith G; Center for Pathogen Research, The University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
  • Frieman MB; Johns Hopkins University, School of Medicine, 720 Rutland Avenue, Ross 1164, Baltimore, MD, 21205, USA.
Nat Commun ; 14(1): 1130, 2023 02 28.
Article in English | MEDLINE | ID: covidwho-2269560
ABSTRACT
SARS-CoV-2 variants have emerged with elevated transmission and a higher risk of infection for vaccinated individuals. We demonstrate that a recombinant prefusion-stabilized spike (rS) protein vaccine based on Beta/B.1.351 (rS-Beta) produces a robust anamnestic response in baboons against SARS-CoV-2 variants when given as a booster one year after immunization with NVX-CoV2373. Additionally, rS-Beta is highly immunogenic in mice and produces neutralizing antibodies against WA1/2020, Beta/B.1.351, and Omicron/BA.1. Mice vaccinated with two doses of Novavax prototype NVX-CoV2373 (rS-WU1) or rS-Beta alone, in combination, or heterologous prime-boost, are protected from challenge. Virus titer is undetectable in lungs in all vaccinated mice, and Th1-skewed cellular responses are observed. We tested sera from a panel of variant spike protein vaccines and find broad neutralization and inhibition of spikeACE2 binding from the rS-Beta and rS-Delta vaccines against a variety of variants including Omicron. This study demonstrates that rS-Beta vaccine alone or in combination with rS-WU1 induces antibody-and cell-mediated responses that are protective against challenge with SARS-CoV-2 variants and offers broader neutralizing capacity than a rS-WU1 prime/boost regimen alone. Together, these nonhuman primate and murine data suggest a Beta variant booster dose could elicit a broad immune response to fight new and future SARS-CoV-2 variants.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Nanoparticles / COVID-19 Vaccines / COVID-19 Type of study: Prognostic study Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2023 Document Type: Article Affiliation country: S41467-022-35606-6

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Nanoparticles / COVID-19 Vaccines / COVID-19 Type of study: Prognostic study Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2023 Document Type: Article Affiliation country: S41467-022-35606-6